Modulation of hepcidin to treat iron deregulation: potential clinical applications
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The secreted peptide hormone hepcidin regulates systemic and local iron homeostasis through degradation of the iron exporter ferroportin. Dysregulation of hepcidin leads to altered iron homeostasis and development of pathological disorders including hemochromatosis, and iron loading and iron restrictive anemias. Therapeutic modulation of hepcidin is a promising method to ameliorate these conditions. Several approaches have been taken to enhance or reduce the effects of hepcidin in vitro and in vivo. Based on these approaches, hepcidin modulating drugs have been developed and are undergoing clinical evaluation. In this article we review the rationale for development of these drugs, the data concerning their safety and efficacy, their therapeutic uses, and potential future prospects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-399 · Cited by 3,664 · cited 3×
“Mutations in TFR2 or HFE result in partial hepcidin insufficiency, leading to a less severe form of HH.[49,50] It is thought that increasing concentrations of holo-transferrin results in the transfer of HFE from TFR1 to TFR2, stabilizing TFR2 and subsequently activating the downstream SMAD pathway.”
BackgroundNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 13×
“[28] Mass spectrometry (MS) methods, including time-offlight MS and high performance liquid chromatographytandem MS, have also been used for the detection of”
BackgroundMethodInfluentialHepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168 · cited 2×
“bioactive peptide hormone.[6,7,9] Hepcidin regulates body iron by binding to FPN, causing the internalization and subsequent degradation of hepci-”
BackgroundPigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697 · cited 4×
“delivery is feasible to the liver,[144] the primary site of systemic hepcidin production.[7] In a related approach, Alnylam Pharmaceuticals, Inc.”
BackgroundInfluentialPositional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621 · cited 1×
“role of hepcidin in promoting cancer growth is still under study, hepcidin appears to be elevated in a number of cancers.[159] Utilizing hepcidin antagonists”
BackgroundSelf-citationHepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417 · cited 1×
“inflammatory regulation of hepcidin was specific for type II acute phase cytokines, particularly Interleukin-6 (IL-6), and not type I cytokines.[53] Specifically, IL-6”
BackgroundSclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 2×
“[14] SOSTDC1, which antagonizes BMP signaling, can also antagonize Wnt signaling by binding to the Wnt receptor LRP5/6.[77] Treatment”
BackgroundLEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
Krause, A., Neitz, S., Mägert, H.-J., Schulz, A., Forssmann, W.-G., Schulz-Knappe, P., & Adermann, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01920-7 · Cited by 1,324 · cited 1×
“Interestingly, hepcidin was first described as an antimicrobial peptide, and it is thought that regulation of hepcidin by inflammation has evolved as a protective mechanism to reduce iron availability for microbes during host infection.[5,52] It”
BackgroundGanz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Cited by
Iron and cancer: recent insights
Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M., & Torti, S. V. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13008 · Cited by 507
Self-citationMitochondria and Iron: current questions
Paul, B. T., Manz, D. H., Torti, F. M., & Torti, S. V. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2016.1268047 · Cited by 423
Self-citationIron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268
Pharmacological Targeting of the Hepcidin/Ferroportin Axis
Sebastiani, G., Wilkinson, N., & Pantopoulos, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00160 · Cited by 127
Iron Deficiency in Obesity and after Bariatric Surgery
Bjørklund, G., Peana, M., Pivina, L., Dosa, A., Aaseth, J., Semenova, Y., Chirumbolo, S., Medici, S., Dadar, M., & Costea, D.-O. (2021) · Biomolecules · doi:10.3390/biom11050613 · Cited by 99
Metadata
- Authors
- Blanchette, N. L., Manz, D. H., Torti, F. M., & Torti, S. V.
- Venue
- Expert Review of Hematology
- Publisher
- Informa UK Limited
- Published
- 2015-12-15
- Volume
- 9
- Issue
- 2
- Pages
- 169-186
- ISSN
- 1747-4086 (ISSN-L)
- 1747-4094
- OpenAlex
- W2220192676
- Cited by
- 59
- References
- 63
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of hepcidin to treat iron deregulation: potential clinical applications. https://app.cochat.ai/papers/10.1586/17474086.2016.1124757
- The paper
- Blanchette, N. L., Manz, D. H., Torti, F. M., & Torti, S. V. (2016). Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Review of Hematology. https://doi.org/10.1586/17474086.2016.1124757
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.